Edition:
India

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

27.91USD
21 Jun 2017
Change (% chg)

-- (--)
Prev Close
$27.91
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,737,595
52-wk High
$28.51
52-wk Low
$19.67

BSX.N

Chart for BSX.N

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health,... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $38,220.00
Shares Outstanding(Mil.): 1,369.40
Dividend: --
Yield (%): --

Financials

EXCLUSIVE: India regulator wants medical devices added to price control list, document shows

NEW DELHI/MUMBAI India's drug-pricing regulator has asked the health ministry to add four more medical devices to a list of products eligible for price controls to reduce costs to patients, which if agreed could be another blow to the country's $5 billion-a-year medical-technology industry.

07 Jun 2017

Exclusive - India regulator wants medical devices added to price control list, document shows

NEW DELHI/MUMBAI India's drug-pricing regulator has asked the health ministry to add four more medical devices to a list of products eligible for price controls to reduce costs to patients, which if agreed could be another blow to the country's $5 billion-a-year medical-technology industry.

07 Jun 2017

BRIEF-Boston Scientific receives CE mark for Vercise Gevia deep brain stimulation system

* Boston Scientific receives CE mark for Vercise™ Gevia™ deep brain stimulation system

06 Jun 2017

BRIEF-Boston Scientific announces positive outcomes from prospective study of bronchial thermoplasty

* Boston Scientific announces positive outcomes from prospective study of bronchial thermoplasty

24 May 2017

BRIEF-Boston Scientific announces positive results from the Reprise III clinical trial

* The Boston Scientific LOTUS™ valve system demonstrated superior efficacy to Corevalve® in global reprise III trial at one year

16 May 2017

BRIEF-Boston Scientific closes Symetis acquisition

* To immediately begin selling Acurate TA and Acurate Neo/TF valve systems in Europe and other geographies outside of U.S. Source text for Eikon: Further company coverage:

16 May 2017

BRIEF-Boston Scientific says positive European registry results for WATCHMAN left atrial appendage closure device

* Boston scientific announces positive european registry results for watchman™ left atrial appendage closure device

12 May 2017

BRIEF-Boston Scientific announces results of study evaluating patients implanted with S-ICD System

* Announced results from U.S. post-market approval study evaluating 'real-world' patients implanted with S-ICD System

11 May 2017

India government panel rejects Boston Scientific plea on stent price caps

NEW DELHI Boston Scientific Corp stands to lose millions of dollars on its high-end heart stent in India after a government panel rejected its request to increase a cap on the price that it can charge for the device.

09 May 2017

BRIEF-Boston Scientific receives FDA approval for resonate family of high-voltage devices

* Boston Scientific receives U.S. FDA approval for resonate™ family of high-voltage devices

09 May 2017

More From Around the Web

Competitors

Earnings vs. Estimates